二甲双胍联合西格列汀治疗2型糖尿病伴代谢综合征的临床效果观察(1)
[摘要] 目的 对二甲双胍联合西格列汀治疗2型糖尿病伴代谢综合征的临床效果观察。方法 随机选取该院2017年5月—2018年5月收治治疗的2型糖尿病伴代谢综合征患者共82例，对这些患者进行分为研究组和对比组两组处理，每组患者41例。对比组实施二甲双胍药物治疗，研究组患者进行二甲双胍联合西格列汀药物联合治疗，对两组患者治疗的效果加以观察和对比分析。 结果 在对患者实施有效治疗之后，研究组患者的空腹胰岛素和空腹血糖以及胰岛素抵抗指数等相关指数水平相对比对比组低，两组差异有统计学意义(P<0.05)，研究组患者的高密度脂蛋白胆固醇想对比对比组产妇高，两组对比差异有统计学意义(P<0.05)，研究组患者C-反应蛋白和肿瘤坏死因子-α等指标水平明显要比对比组低，两组对比差异明显(P<0.05)。 结论 二甲双胍联合西格列汀对2型糖尿病伴代谢综合征疾病进行治疗，其能够促使患者自身的糖脂代谢得到有效改善，使得患者的机体炎性反应能够有效减轻，并且促使患者的生活质量得到提升。
[关键词] 二甲双胍；西格列汀；2型糖尿病伴代谢综合征；临床效果；观察
[中图分类号] R587 [文獻标识码] A [文章编号] 1672-4062(2018)12(a)-0189-02
Clinical Observation of Metformin Combined with Sitagliptin in the Treatment of Type 2 Diabetes with Metabolic Syndrome
LI Yan， HOU Xin-ying
Department of Internal Medicine， Daqing Oilfield Chengfeng Hospital， Daqing， Heilongjiang Province， 163411 China
[Abstract] Objective To observe the clinical effect of metformin combined with sitagliptin in the treatment of type 2 diabetes with metabolic syndrome. Methods A total of 82 patients with type 2 diabetes mellitus and metabolic syndrome treated in our hospital from May 2017 to May 2018 were randomly selected. The patients were divided into two groups： study group and control group， with 41 patients in each group. The patients in the control group were treated with metformin. The patients in the study group were treated with metformin combined with sitagliptin. The effects of the two groups were observed and compared. Results After effective treatment of patients， the levels of fasting insulin and fasting blood glucose and insulin resistance index in the study group were lower than those in the control group. The difference between the two groups was significant (P<0.05). The high-density lipoprotein cholesterol in the study group was higher than that of the maternal of the control group. The difference between the two groups was significant (P<0.05). The levels of C-reactive protein and tumor necrosis factor-α in the study group were significantly lower than those in the control group. The difference between the two groups was significant (P<0.05). Conclusion Metformin combined with sitagliptin in the treatment of type 2 diabetes with metabolic syndrome can promote the patient's own glucose and lipid metabolism， which can effectively reduce the body's inflammatory response and promote the quality of life of patients.
[Key words] Metformin； Sitagliptin； Type 2 diabetes with metabolic syndrome； Clinical effect； Observation
2型糖尿病属于具有多发性特点的内分泌疾病，其是人体患者机体糖脂代谢出现异常情况，在这一过程中，容易出现并发疾病情况，通常情况下并发代谢综合征，2型糖尿病伴代谢综合征疾病的病情是较为复杂的，其血糖在控制的时候存在着一定难度，患者体内代谢能够平稳运行比较困难。患者机体糖脂代谢的现象能够得以改善，并且能够使炎性反应减轻等对于2型糖尿病伴代谢综合征患者的预后也具有重要影响，在当前阶段中，对患者临床治疗的时候，2型糖尿病伴代谢综合征患者存在着多个系统代谢紊乱的现象，也就容易造成治疗效果不理想的情况发生[1]。因此，更多研究者对联合用药的情况加以观察和研究，对患者治疗更加安全有效的方式探讨。该研究对该院2017年5月—2018年5月收治治疗的2型糖尿病伴代谢综合征患者82例情况分析，对二甲双胍联合西格列汀治疗2型糖尿病伴代谢综合征的临床效果观察，现报道如下。, 百拇医药(李岩 侯新颖)
[关键词] 二甲双胍；西格列汀；2型糖尿病伴代谢综合征；临床效果；观察
[中图分类号] R587 [文獻标识码] A [文章编号] 1672-4062(2018)12(a)-0189-02
Clinical Observation of Metformin Combined with Sitagliptin in the Treatment of Type 2 Diabetes with Metabolic Syndrome
LI Yan， HOU Xin-ying
Department of Internal Medicine， Daqing Oilfield Chengfeng Hospital， Daqing， Heilongjiang Province， 163411 China
[Abstract] Objective To observe the clinical effect of metformin combined with sitagliptin in the treatment of type 2 diabetes with metabolic syndrome. Methods A total of 82 patients with type 2 diabetes mellitus and metabolic syndrome treated in our hospital from May 2017 to May 2018 were randomly selected. The patients were divided into two groups： study group and control group， with 41 patients in each group. The patients in the control group were treated with metformin. The patients in the study group were treated with metformin combined with sitagliptin. The effects of the two groups were observed and compared. Results After effective treatment of patients， the levels of fasting insulin and fasting blood glucose and insulin resistance index in the study group were lower than those in the control group. The difference between the two groups was significant (P<0.05). The high-density lipoprotein cholesterol in the study group was higher than that of the maternal of the control group. The difference between the two groups was significant (P<0.05). The levels of C-reactive protein and tumor necrosis factor-α in the study group were significantly lower than those in the control group. The difference between the two groups was significant (P<0.05). Conclusion Metformin combined with sitagliptin in the treatment of type 2 diabetes with metabolic syndrome can promote the patient's own glucose and lipid metabolism， which can effectively reduce the body's inflammatory response and promote the quality of life of patients.
[Key words] Metformin； Sitagliptin； Type 2 diabetes with metabolic syndrome； Clinical effect； Observation
2型糖尿病属于具有多发性特点的内分泌疾病，其是人体患者机体糖脂代谢出现异常情况，在这一过程中，容易出现并发疾病情况，通常情况下并发代谢综合征，2型糖尿病伴代谢综合征疾病的病情是较为复杂的，其血糖在控制的时候存在着一定难度，患者体内代谢能够平稳运行比较困难。患者机体糖脂代谢的现象能够得以改善，并且能够使炎性反应减轻等对于2型糖尿病伴代谢综合征患者的预后也具有重要影响，在当前阶段中，对患者临床治疗的时候，2型糖尿病伴代谢综合征患者存在着多个系统代谢紊乱的现象，也就容易造成治疗效果不理想的情况发生[1]。因此，更多研究者对联合用药的情况加以观察和研究，对患者治疗更加安全有效的方式探讨。该研究对该院2017年5月—2018年5月收治治疗的2型糖尿病伴代谢综合征患者82例情况分析，对二甲双胍联合西格列汀治疗2型糖尿病伴代谢综合征的临床效果观察，现报道如下。, 百拇医药(李岩 侯新颖)